One of the major challenges facing the field of Hematology and Oncology is that of the secondary hematologic disorders. These disorders are becoming increasingly common, at least in part because of the effectiveness of high dose cytotoxic therapy in the treatment of patients with malignant disease. As many as 10% of patients cured of malignant disease by therapy with DNA damaging agents will develop a hematologic disorder and this percentage may be double in patients who are treated with autologous stem cell transplantation as part of their curative therapy. The rapid clinical course of both secondary MDS and secondary AML makes the development of these disorders in patients already cured of one malignancy especially disturbing. While a great deal of information is available regarding a variety of molecular genetic abnormalities which have been detected in MDS and AML, little or no information is available with respect to how often multiple genetic abnormalities are present and little information is available regarding the biological consequences of these abnormalities. The lack of information in these areas severely restricts our understanding of the development of MDS and AML. The studies which will be conducted as part of this Program Project will focus on the most common molecular genetic lesions of these disorders, will study these lesions simultaneously in the same patients, the in vivo and in vitro biological characteristics of the abnormal cells will be identified and related to the genetic lesions which are present. Parallel in vitro studies will help to define the mechanisms underlying these associations. Special emphasis will be placed in two areas: 1 - on MDS and AML characterized by deletions of chromosomes 5 and/or 7 q and 2 - on aberrant cytokine production in these diseases and the role which it plays in the genesis of both MDS and AML. These two areas of particular interest, the former because the stability of these genetic lesions as the disease evolves from MDS to AML strongly suggests a key role of these lesions in the genesis of these disorders and the second because of our demonstrated ability to suppress abnormal cytokine production in vivo in patients and thus alter the behavior of both MDS and AML cells. This later ability offers the prospect of rapidly applying the results of the laboratory studies to the clinic to improve treatment outcome in both MDS and AML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA075606-02
Application #
2712894
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1997-08-08
Project End
2002-05-31
Budget Start
1998-08-31
Budget End
1999-05-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Raza, Azra; Buonamici, Silvia; Lisak, Laurie et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28:791-803
Raza, A; Candoni, A; Khan, U et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45:2099-104
Candoni, Anna; Silvestri, Federico; Buonamici, Silvia et al. (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 41:13-20
Huang, X K; Meyer, P; Li, B et al. (2003) The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro. Leuk Lymphoma 44:157-64
Gladstone, Betty; Sivaraman, Smitha; Galili, Naomi et al. (2003) A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leuk Res 27:529-37
Reddy, Poluru L; Shetty, Vilasini T; Dutt, Diya et al. (2002) Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol 116:564-75
Allampallam, Krishnan; Shetty, Vilasini; Mundle, Suneel et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-97
Shetty, Vilasini; Hussaini, Seema; Alvi, Sairah et al. (2002) Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. Br J Haematol 116:817-25
Zorat, F; Shetty, V; Dutt, D et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115:881-94
Preisler, H D (2001) Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. Cancer Treat Res 108:185-230

Showing the most recent 10 out of 40 publications